Differentiating Struma ovarii from other diseases: Difference between revisions
Jump to navigation
Jump to search
| Line 105: | Line 105: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Variable | | style="padding: 5px 5px; background: #F5F5F5;" | Variable | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow | | style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Low or absent in the thyroid gland | |||
* Present in the pelvis | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Abdominal RAIU | | style="padding: 5px 5px; background: #F5F5F5;" | Abdominal RAIU | ||
|} | |} | ||
Revision as of 13:52, 24 August 2017
|
Struma ovarii Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Differentiating Struma ovarii from other diseases On the Web |
|
American Roentgen Ray Society Images of Differentiating Struma ovarii from other diseases |
|
Differentiating Struma ovarii from other diseases in the news |
|
Risk calculators and risk factors for Differentiating Struma ovarii from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
Struma ovarii which is potentially malignant should be differentiated from an ovarian mass with cystic, solid, or mixed cystic and solid structure. Struma ovarii must be differentiated from other diseases like benign and malignant ovarian neoplasm, ovarian cyst, endometrioma and tubo-ovarian abscess.
Differentiating Struma ovarii from other Diseases
- Struma ovarii which is potentially malignant should be differentiated from an ovarian mass with cystic, solid, or mixed cystic and solid structure. [1]
- Various benign and malignant ovarian neoplasms
- Endometrioma
- Ectopic Pregnancy
- Metastatic thyroid cancer to the ovary
- Ovarian cyst(Physiological)
- Tubo-ovarian abscess
- Hydrosalpinx
- Hyperthyroidism
- Struma ovarii must be differentiated from other causes of hyperthyroidism such as Grave's disease and toxic nodular goiter.
| Cause of thyrotoxicosis | TSH receptor antibodies | Thyroid US | Color flow Doppler | Radioactive iodine uptake/Scan | Other features |
|---|---|---|---|---|---|
| Graves' disease | + | Hypoechoic pattern | ? | ? | Ophthalmopathy, dermopathy, acropachy |
| Toxic nodular goiter | - | Multiple nodules | - | Hot nodules at thyroid scan | - |
| Toxic adenoma | - | Single nodule | - | Hot nodule | - |
| Subacute thyroiditis | - | Heterogeneous hypoechoic areas | Reduced/absent flow | ? | Neck pain, fever, and elevated inflammatory index |
| Painless thyroiditis | - | Hypoechoic pattern | Reduced/absent flow | ? | - |
| Amiodarone induced thyroiditis-Type 1 | - | Diffuse or nodular goiter | ?/Normal/? | ? but higher than in Type 2 | High urinary iodine |
| Amiodarone induced thyroiditis-Type 2 | - | Normal | Absent | ?/absent | High urinary iodine |
| Central hyperthyroidism | - | Diffuse or nodular goiter | Normal/? | ? | Inappropriately normal or high TSH |
| Trophoblastic disease | - | Diffuse or nodular goiter | Normal/? | ? | - |
| Factitious thyrotoxicosis | - | Variable | Reduced/absent flow | ? | ? Serum thyroglobulin |
| Struma ovarii | - | Variable | Reduced/absent flow |
|
Abdominal RAIU |
| Disease | Findings | |
|---|---|---|
| Thyroiditis | Direct chemical toxicity with inflammation | Amiodarone, sunitinib, pazopanib, axitinib, and other tyrosine kinase inhibitors may also be associated with a destructive thyroiditis.[10][11] |
| Radiation thyroiditis | Patients treated with radioiodine may develop thyroid pain and tenderness 5 to 10 days later, due to radiation-induced injury and necrosis of thyroid follicular cells and associated inflammation. | |
| Drugs that interfere with the immune system | Interferon-alfa is a well-known cause of thyroid abnormality. It mostly leads to the development of de novo antithyroid antibodies.[12] | |
| Lithium | Patients treated with lithium are at a high risk of developing painless thyroiditis and Graves' disease. | |
| Palpation thyroiditis | Manipulation of the thyroid gland during thyroid biopsy or neck surgery and vigorous palpation during the physical examination may cause transient hyperthyroidism. | |
| Exogenous and ectopic hyperthyroidism | Factitious ingestion of thyroid hormone | The diagnosis is based on the clinical features, laboratory findings, and 24-hour radioiodine uptake.[13] |
| Acute hyperthyroidism from a levothyroxine overdose | The diagnosis is based on the clinical features, laboratory findings, and 24-hour radioiodine uptake.[14] | |
| Struma ovarii | Functioning thyroid tissue is present in an ovarian neoplasm. | |
| Functional thyroid cancer metastases | Large bony metastases from widely metastatic follicular thyroid cancer cause symptomatic hyperthyroidism. | |
| Hashitoxicosis | It is an autoimmune thyroid disease that initially presents with hyperthyroidism and a high radioiodine uptake caused by TSH-receptor antibodies similar to Graves' disease. It is then followed by the development of hypothyroidism due to the infiltration of the thyroid gland with lymphocytes and the resultant autoimmune-mediated destruction of thyroid tissue, similar to chronic lymphocytic thyroiditis.[15] | |
| Toxic adenoma and toxic multinodular goiter | Toxic adenoma and toxic multinodular goiter are results of focal/diffuse hyperplasia of thyroid follicular cells independent of TSH regulation. Findings of single or multiple nodules are seen on physical examination or thyroid scan.[16] | |
| Iodine-induced hyperthyroidism | It is uncommon but can develop after an iodine load, such as administration of contrast agents used for angiography or computed tomography (CT), or iodine-rich drugs such as amiodarone. | |
| Trophoblastic disease and germ cell tumors | Thyroid-stimulating hormone and HCG have a common alpha-subunit and a beta-subunit with considerable homology. As a result, HCG has weak thyroid-stimulating activity and high titer HCG may mimic hyperthyroidism.[17] | |
References
- ↑ Kraemer B, Grischke EM, Staebler A, Hirides P, Rothmund R (2011). "Laparoscopic excision of malignant struma ovarii and 1 year follow-up without further treatment". Fertil Steril. 95 (6): 2124.e9–12. doi:10.1016/j.fertnstert.2010.12.047. PMID 21269611.
- ↑ Yoo SC, Chang KH, Lyu MO, Chang SJ, Ryu HS, Kim HS (2008). "Clinical characteristics of struma ovarii". J Gynecol Oncol. 19 (2): 135–8. doi:10.3802/jgo.2008.19.2.135. PMC 2676458.
- ↑ Park CH, Jung MH, Ji YI (2015). "Risk factors for malignant transformation of mature cystic teratoma". Obstet Gynecol Sci. 58 (6): 475–80. doi:10.5468/ogs.2015.58.6.475. PMC 4663225. PMID 26623411.
- ↑ Wee JY, Li X, Chern BS, Chua IS (2015). "Struma ovarii: management and follow-up of a rare ovarian tumour". Singapore Med J. 56 (1): 35–9. PMC 4325564. PMID 25640097.
- ↑ Dujardin MI, Sekhri P, Turnbull LW (2014). "Struma ovarii: role of imaging?". Insights Imaging. 5 (1): 41–51. doi:10.1007/s13244-013-0303-3. PMC 3948908. PMID 24357453.
- ↑ Mostaghel N, Enzevaei A, Zare K, Fallahian M (2012). "Struma ovarii associated with Pseudo-Meig's syndrome and high serum level of CA 125; a case report". J Ovarian Res. 5: 10. doi:10.1186/1757-2215-5-10. PMC 3350392. PMID 22436494.
- ↑ Tanimanidis P, Chatzistamatiou K, Nikolaidou A, Kaplanis K (2014). "Struma ovarii. A case report". Hippokratia. 18 (4): 357–8. PMC 4453812. PMID 26052205.
- ↑ Yücesoy G, Cakiroglu Y, Muezzinoglu B, Besnili B, Yucesoy I (2010). "Malignant struma ovarii: a case report". J. Korean Med. Sci. 25 (2): 327–9. doi:10.3346/jkms.2010.25.2.327. PMID 20119594.
- ↑ Rosenblum, NG; LiVolsi, VA; Edmonds, PR; Mikuta, JJ (1989). "Malignant struma ovarli". International Journal of Gynecology & Obstetrics. 30 (1): 80–81. doi:10.1016/0020-7292(89)90235-X. ISSN 0020-7292.
- ↑ Lambert M, Unger J, De Nayer P, Brohet C, Gangji D (1990). "Amiodarone-induced thyrotoxicosis suggestive of thyroid damage". J. Endocrinol. Invest. 13 (6): 527–30. PMID 2258582.
- ↑ Ahmadieh H, Salti I (2013). "Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment". Biomed Res Int. 2013: 725410. doi:10.1155/2013/725410. PMC 3824811. PMID 24282820.
- ↑ Vialettes B, Guillerand MA, Viens P, Stoppa AM, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D (1993). "Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies". Acta Endocrinol. 129 (1): 31–8. PMID 8351956.
- ↑ Cohen JH, Ingbar SH, Braverman LE (1989). "Thyrotoxicosis due to ingestion of excess thyroid hormone". Endocr. Rev. 10 (2): 113–24. doi:10.1210/edrv-10-2-113. PMID 2666114.
- ↑ Jha S, Waghdhare S, Reddi R, Bhattacharya P (2012). "Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis". Thyroid. 22 (12): 1283–6. doi:10.1089/thy.2011.0353. PMID 23067331.
- ↑ Fatourechi V, McConahey WM, Woolner LB (1971). "Hyperthyroidism associated with histologic Hashimoto's thyroiditis". Mayo Clin. Proc. 46 (10): 682–9. PMID 5171000.
- ↑ Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G (1991). "High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland". J. Intern. Med. 229 (5): 415–20. PMID 2040867.
- ↑ Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA (2010). "Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors". Ann. Oncol. 21 (1): 104–8. doi:10.1093/annonc/mdp265. PMID 19605510.